|
HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 1
|
0.300 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
|
Parkinson Disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Parkinson's disease (n = 86) and control (n = 161) DNA were genotyped for 19 regulatory region tagging single-nucleotide polymorphisms (SNPs) within nine genes (APP, ADAM10, BACE1, BACE2, PSEN1, PSEN2, PEN2, NCSTN, and APH1B) involved in the cleavage of APP.
|
25808939 |
2015 |
|
Down Syndrome
|
0.050 |
Biomarker
|
disease |
BEFREE |
BACE2 could be involved in the Alzheimer-like neuropathology of Down syndrome, as well as in Alzheimer's disease linked to chromosome 21 but not showing mutations in APP.
|
10965118 |
2000 |
|
Complete Trisomy 21 Syndrome
|
0.050 |
Biomarker
|
disease |
BEFREE |
BACE2 could be involved in the Alzheimer-like neuropathology of Down syndrome, as well as in Alzheimer's disease linked to chromosome 21 but not showing mutations in APP.
|
10965118 |
2000 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
BACE2 could be involved in the Alzheimer-like neuropathology of Down syndrome, as well as in Alzheimer's disease linked to chromosome 21 but not showing mutations in APP.
|
10965118 |
2000 |
|
Adenoma of large intestine
|
0.010 |
Biomarker
|
disease |
BEFREE |
ALP56 may contribute to colorectal adenoma formation and to an exophytic growth pattern in these adenomas.
|
12802606 |
2004 |
|
Adenoma
|
0.010 |
Biomarker
|
group |
BEFREE |
ALP56 may contribute to colorectal adenoma formation and to an exophytic growth pattern in these adenomas.
|
12802606 |
2004 |
|
DOWN SYNDROME CRITICAL REGION
|
0.020 |
Biomarker
|
disease |
BEFREE |
BACE2 is homologous to BACE1, a beta-secretase that is involved in the amyloidogenic pathway of amyloid precursor protein (APP), and maps to the Down syndrome critical region of chromosome 21.
|
19840121 |
2010 |
|
Alzheimer's Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
BACE2 activity did not change significantly in the AD brain, and was not related to Abeta concentration.
|
19968762 |
2010 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
BACE2 (β-site APP-cleaving enzyme 2) is a protease localized in the brain, where it appears to play a role in the development of Alzheimer disease (AD).
|
25342134 |
2015 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Beta-site APP-cleaving enzyme 2, BACE2, is an aspartyl protease commonly associated with BACE1, a related homolog responsible for amyloid processing in the brain and strongly implicated in Alzheimer's disease.
|
26840340 |
2016 |
|
Liver carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
ASP-1 at a concentration of 128 µg/mL did not show haemolytic activity, and no cytotoxicity was observed against hepatic carcinoma and breast carcinoma cell lines at the same concentration.
|
28887200 |
2018 |
|
Breast Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
ASP-1 at a concentration of 128 µg/mL did not show haemolytic activity, and no cytotoxicity was observed against hepatic carcinoma and breast carcinoma cell lines at the same concentration.
|
28887200 |
2018 |
|
Senile Plaques
|
0.020 |
Biomarker
|
disease |
BEFREE |
BACE2 is an aspartyl protease to cleave APP to prevent the generation of Aβ, a central component of neuritic plaques in Alzheimer's brain.
|
29703946 |
2018 |
|
Diabetes
|
0.010 |
Biomarker
|
disease |
BEFREE |
BACE2 has been recognized as an exciting new target for type 2 diabetes.
|
30637955 |
2019 |
|
Diabetes Mellitus
|
0.010 |
Biomarker
|
group |
BEFREE |
BACE2 has been recognized as an exciting new target for type 2 diabetes.
|
30637955 |
2019 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
A major challenge in the development of β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors for the treatment of Alzheimer's disease is the alignment of potency, drug-like properties, and selectivity over related aspartyl proteases such as Cathepsin D (CatD) and BACE2.
|
29613789 |
2018 |
|
Mammary Neoplasms
|
0.010 |
AlteredExpression
|
group |
LHGDN |
A novel aspartic protease gene, ALP56, is up-regulated in human breast cancer independently from the cathepsin D gene.
|
12611455 |
2003 |
|
MRSA - Methicillin resistant Staphylococcus aureus infection
|
0.010 |
Biomarker
|
disease |
BEFREE |
A strong antistaphylococcal peptide (ASP-1) from Bacillus subtilis URID 12.1 strain that is active against cefoxitin- and methicillin-resistant Staphylococcus aureus clinical isolates was purified to homogeneity by solvent extraction, silica gel-based adsorption chromatography and reversed-phase high-performance liquid chromatography.
|
28887200 |
2018 |
|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Additionally, we found increased expression levels of genes that are considered to be associated with AD (BACE2, RCAN1, ETS2, TMED10), as compared to healthy controls.
|
28059787 |
2017 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
APP and BACE2 are 2 genes located in chromosome 21 and related to AD.
|
24462566 |
2014 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
As glia are 10 times more abundant in brain compared with neurons, our data indicate that BACE2 could indeed contribute to Abeta generation in the brains of Alzheimer disease and, in particular, Down syndrome patients.
|
15987683 |
2005 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Based on its high catalytic efficiency, its ability to degrade Aß intracellularly, and other characteristics, BACE2 represents a particulary strong therapeutic candidate for the treatment or prevention of AD.
|
22986058 |
2012 |
|
AICARDI-GOUTIERES SYNDROME
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Both strains are genetically identical to the AGS susceptible DBA/2 (D2) strain except for a small amount of C57BL/6N (B6N) genome surrounding the Ahr locus and encompassing the Asp1 locus.
|
10656108 |
1998 |
|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Chromosome 21 BACE2 haplotype associates with Alzheimer's disease: a two-stage study.
|
16023140 |
2005 |